Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $227.1M | $381.6M | $541.1M | $697.9M | $1,187.4M | $1,513.5M | $1,634.3M | $1,470.4M | $1,487.9M | $1,249.3M | $1,204.6M | $1,280.5M | $1,437.5M | $1,533.7M | $1,662.6M | $1,955.6M | $2,071.5M | $2,214.1M | $2,223.2M | $2,236.4M |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Amedisys, Inc.'s last 12-month Revenue is $2,321.1M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Amedisys, Inc.'s Revenue growth was 4.2%. The average annual Revenue growth rates for Amedisys, Inc. have been 3.1% over the past three years, 4.2% over the past five years.
Over the last year, Amedisys, Inc.'s Revenue growth was 4.2%, which is higher than industry growth of 0.2%. It indicates that Amedisys, Inc.'s Revenue growth is Good.